Regeneron (REGN) jumps 14% after disclosing that its Eylea eye drug generated $24M-25M in sales...

|About: Regeneron Pharmaceuticals... (REGN)|By:, SA News Editor

Regeneron (REGN) jumps 14% after disclosing that its Eylea eye drug generated $24M-25M in sales in the six weeks after November 21, slaying a Q4 anlayst forecast of $5M. Regeneron also predicted that 2012 revenue from the medicine would reach $140M-160M.